Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Afamitresgene autoleucel - Adaptimmune

Drug Profile

Afamitresgene autoleucel - Adaptimmune

Alternative Names: ADP A2M4; afami-cel - adaptimmune; MAGE-A4 SPEAR T-cell therapy; MAGE-A4 TCR; MAGE-A4-SPEAR-T-cell-therapy-Adaptimmune; MAGE-A4ᶜ¹º³²T; Melanoma-associated antigen A4-specific T-cells - Adaptimmune

Latest Information Update: 08 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adaptimmune
  • Developer Adaptimmune; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Synovial sarcoma
  • Phase II Head and neck cancer; Myxoid liposarcoma
  • No development reported Haematological malignancies

Most Recent Events

  • 06 Mar 2023 Adaptimmune Therapeutics plans to file Biologics Licesnse Application (BLA) to the US FDA for Synovial sarcoma in mid year of 2023
  • 06 Mar 2023 Adaptimmune and GOG Foundation plans a phase II trial for Ovarian Cancer (Monotherapy, Combination-therapy, Recurrent) in March 2023 (IV, Infusion) (NCT05601752)
  • 31 Dec 2022 Preregistration for Synovial sarcoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top